From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
CAS Number
PubChem CID
Chemical and physical data
Molar mass163.219 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.[1][2][3]


  1. ^ Jain, K. K. (2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current Opinion in Investigational Drugs. 5 (1): 76–81. PMID 14983978.
  2. ^ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.
  3. ^ Xu, Naxing; Kim, Grace E.; Gregg, Hope; Wagdy, Azza; Swaine, Brendan A.; Chang, Min S.; El-Shourbagy, Tawakol A. (September 2004). "Automated 96-well liquid–liquid back extraction liquid chromatography–tandem mass spectrometry method for the determination of ABT-202 in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 36 (1): 189–195. doi:10.1016/j.jpba.2004.05.013.